Cost-Effectiveness of Pharmacogenomic and Pharmacogenetic Test-Guided Personalized Therapies: A Systematic Review of the Approved Active Substances for Personalized Medicine in Germany
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cost-Effectiveness of Pharmacogenomic and Pharmacogenetic Test-Guided Personalized Therapies: A Systematic Review of the Approved Active Substances for Personalized Medicine in Germany
Authors
Keywords
Abacavir, Azathioprine, Carbamazepine, Cetuximab, Cost-effectiveness, Personalized medicine, Pharmacogenetic test, Targeted therapy
Journal
ADVANCES IN THERAPY
Volume 33, Issue 9, Pages 1461-1480
Publisher
Springer Nature
Online
2016-07-12
DOI
10.1007/s12325-016-0376-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cost-effectiveness of screening forHLA-A*31:01prior to initiation of carbamazepine in epilepsy
- (2015) Catrin O. Plumpton et al. EPILEPSIA
- Methods for identification and confirmation of targeted subgroups in clinical trials: A systematic review
- (2015) Thomas Ondra et al. Journal of Biopharmaceutical Statistics
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Reducing hypersensitivity reactions with HLA-B*5701 genotyping before abacavir prescription
- (2015) Ritika Kapoor et al. Pharmacogenetics and Genomics
- Cost-effectiveness of one-time genetic testing to minimize lifetime adverse drug reactions
- (2015) O Alagoz et al. PHARMACOGENOMICS JOURNAL
- The Cost-Effectiveness of a Pharmacogenetic Test: A Trial-Based Evaluation of TPMT Genotyping for Azathioprine
- (2014) Alexander J. Thompson et al. VALUE IN HEALTH
- What is personalized medicine: sharpening a vague term based on a systematic literature review
- (2013) Sebastian Schleidgen et al. BMC Medical Ethics
- Economic evaluation of HLA-B*15:02 screening for carbamazepine-induced severe adverse drug reactions in Thailand
- (2013) Waranya Rattanavipapong et al. EPILEPSIA
- Pharmacogenetics in clinical practice: how far have we come and where are we going?
- (2013) Julie A Johnson PHARMACOGENOMICS
- Pharmacogenetics and pharmacogenomics: a bridge to individualized cancer therapy
- (2013) Liming Weng et al. PHARMACOGENOMICS
- Factors affecting the development of adverse drug reactions (Review article)
- (2013) Muaed Jamal Alomar SAUDI PHARMACEUTICAL JOURNAL
- The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers
- (2012) A J Atherly et al. BRITISH JOURNAL OF CANCER
- Pharmacogenomics of adverse drug reactions: implementing personalized medicine
- (2012) C.-Y. Wei et al. HUMAN MOLECULAR GENETICS
- Cost-Effectiveness Analysis of Screening for KRAS and BRAF Mutations in Metastatic Colorectal Cancer
- (2012) Ajay S. Behl et al. JNCI-Journal of the National Cancer Institute
- Cost-Effectiveness Analysis of KRAS Testing and Cetuximab as Last-Line Therapy for Colorectal Cancer
- (2012) Takeru Shiroiwa et al. Molecular Diagnosis & Therapy
- Cost-effectiveness of HLA-B*1502 genotyping in adult patients with newly diagnosed epilepsy in Singapore
- (2012) D. Dong et al. NEUROLOGY
- General principles of investigating and managing drug allergy
- (2011) Anthony Frew BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung
- (2011) Gilberto de Lima Lopes et al. CANCER
- Pharmacogenomic testing: Relevance in medical practice: Why drugs work in some patients but not in others
- (2011) J. P. KITZMILLER et al. CLEVELAND CLINIC JOURNAL OF MEDICINE
- KRAS and BRAF Mutation Analysis in Metastatic Colorectal Cancer: A Cost-effectiveness Analysis from a Swiss Perspective
- (2011) P. R. Blank et al. CLINICAL CANCER RESEARCH
- Professional Perspectives About Pharmacogenetic Testing and Managing Ancillary Findings
- (2011) Susanne B. Haga et al. Genetic Testing and Molecular Biomarkers
- Personalizing medicine with clinical pharmacogenetics
- (2011) Stuart A. Scott GENETICS IN MEDICINE
- Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany
- (2011) Arthi Vijayaraghavan et al. INTERNATIONAL JOURNAL OF CANCER
- Facilitating Clinical Implementation of Pharmacogenomics
- (2011) David A. Mrazek et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Secondary Somatic Mutations Restoring BRCA1/2 Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas
- (2011) Barbara Norquist et al. JOURNAL OF CLINICAL ONCOLOGY
- Economic Evaluation of Genomic Test–Directed Chemotherapy for Early-Stage Lymph Node–Positive Breast Cancer
- (2011) Peter S. Hall et al. JNCI-Journal of the National Cancer Institute
- Acute Mesenteric Infarction Associated with Atrial Fibrillation
- (2011) Jia-Ming Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- A cost effectiveness analysis of thiopurine methyltransferase testing for guiding 6-mercaptopurine dosing in children with acute lymphoblastic leukemia
- (2011) Jennifer R. Donnan et al. PEDIATRIC BLOOD & CANCER
- Adverse drug reactions in Germany: direct costs of internal medicine hospitalizations
- (2011) Dominik Rottenkolber et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Pharmacogenetics, Pharmacogenomics, and Individualized Medicine
- (2011) Q. Ma et al. PHARMACOLOGICAL REVIEWS
- Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines
- (2010) D. Bovelli et al. ANNALS OF ONCOLOGY
- Human epidermal growth factor receptor 2 expression in early breast cancer patients: a Swiss cost–effectiveness analysis of different predictive assay strategies
- (2010) Patricia R. Blank et al. BREAST CANCER RESEARCH AND TREATMENT
- Cost-effectiveness analysis of HLA-B*5701 typing in the prevention of hypersensitivity to abacavir in HIV+ patients in Spain
- (2010) Diana Nieves Calatrava et al. ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA
- Pharmacogenetic tests in cancer chemotherapy: what physicians should know for clinical application
- (2010) Soo-Youn Lee et al. JOURNAL OF PATHOLOGY
- Thiopurine S-Methyltranferase Testing in Idiopathic Pulmonary Fibrosis: A Pharmacogenetic Cost-Effectiveness Analysis
- (2010) Jared T. Hagaman et al. LUNG
- Economic Efficiency of Genetic Screening to Inform the Use of Abacavir Sulfate in the Treatment of HIV
- (2010) Teresa L. Kauf et al. PHARMACOECONOMICS
- Predictive and prognostic molecular markers for cancer medicine
- (2010) Sunali Mehta et al. Therapeutic Advances in Medical Oncology
- Pharmacogenetics and pharmacogenomics of anticancer agents
- (2009) R. S. Huang et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Role of pharmacogenomics in drug discovery and development
- (2009) C Adithan et al. INDIAN JOURNAL OF PHARMACOLOGY
- Pharmacogenomics, Evidence, and the Role of Payers
- (2009) P.A. Deverka Public Health Genomics
- The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV
- (2008) Bruce R Schackman et al. AIDS
- The Potential Clinical and Economic Outcomes of Pharmacogenomic Approaches to EGFR-Tyrosine Kinase Inhibitor Therapy in Non–Small-Cell Lung Cancer
- (2008) Josh J. Carlson et al. VALUE IN HEALTH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started